ORAMED PHARMACEUTICALS INC.ORMPEarnings & Financial Report

Nasdaq · pharmaceutical industry

Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.

Revenue

Gross Profit

Operating Profit

$-2.4M

Net Profit

$48.4M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$1.13

ORAMED PHARMACEUTICALS INC. Q3 2025 Financial Summary

ORAMED PHARMACEUTICALS INC. reported revenue of $0 for Q3 2025, with a net profit of $48.4M (N/A margin). Cost of goods sold was $0, operating expenses totaled $2.4M.

Key Financial Metrics

Total Revenue	$0
Net Profit	$48.4M
Gross Margin	N/A
Operating Margin	N/A
Report Period	Q3 2025

ORAMED PHARMACEUTICALS INC. Annual Revenue by Year

ORAMED PHARMACEUTICALS INC. annual revenue history includes year-by-year totals (for example, 2023 revenue was $1.3M).

Year	Annual Revenue
2023	$1.3M
2022	$2.7M

Income Statement

	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2025	Q2 2025	Q3 2025
Revenue	$681000	$666000	$674000	$0	$0	$2.0M	$0	$0
YoY Growth	1.0%	0.0%	0.0%	N/A	N/A	N/A	N/A	N/A

Balance Sheet

	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2025	Q2 2025	Q3 2025
Assets	$161.6M	$159.8M	$156.3M	$230.9M	$220.6M	$147.5M	$161.7M	$220.5M
Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Equity	$151.8M	$151.0M	$151.5M	$149.1M	$163.8M	$140.8M	$154.5M	$203.3M